Investor seeks revamp of Genzyme's executive lineup

04/15/2010 | Boston Herald

Matrix Asset Advisors is urging Genzyme's board to replace Henri Termeer as CEO and accept activist-investor Carl Icahn's board nominees, two of whom are directors at Biogen Idec, a major manufacturer of multiple sclerosis drugs. However, recent tests showing that Genzyme's blood cancer drug Campath is effective in patients with MS could threaten Icahn's proxy challenge.

View Full Article in:

Boston Herald

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC